BC
VERA icon

Bridgefront Capital’s Vera Therapeutics VERA Stock Holding History

Bridgefront Capital’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7,715
Closed -$310K – 766
2026
Q1 		$310K Buy
+7,715
New +$332K 0.08% 387

Other funds holding VERA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bridgefront Capital's VERA Position: Q2 2026 in Review

Bridgefront Capital sold out of Vera Therapeutics (VERA) in Q2 2026, closing a stake of 7,715 shares — an estimated $310K sold.

Bridgefront Capital first reported a position in VERA in Q1 2026 and held it in 1 quarter. The position peaked at $310K in Q1 2026. 219 funds tracked by Wall St. Rank hold VERA as of Q2 2026.

  • Bridgefront Capital reported no remaining Vera Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Bridgefront Capital sold 7,715 Vera Therapeutics shares in Q2 2026, an estimated $310K.
  • Bridgefront Capital first reported a position in Vera Therapeutics in Q1 2026 and held it in 1 quarter.
  • Bridgefront Capital's Vera Therapeutics position peaked at $310K in Q1 2026.
  • 219 funds tracked by Wall St. Rank held Vera Therapeutics as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.